Select your timezone:

Organ, tissue and organoids manufacturing

Friday October 27, 2023 - 12:00 to 13:30

Room: Indigo H

228.1 Hydrogel-based, prevascularized, retrievable endocrine construct to treat Type 1 Diabetes

Fanny Lebreton, Switzerland

Research collaborator
Surgery
University of Geneva and Geneva University Hospitals

Abstract

Hydrogel-based, prevascularized, retrievable endocrine construct to treat Type 1 Diabetes

Kevin Bellofatto1,2,3,4, Fanny Lebreton1,2,3, Reine Hanna1,2,3,4, Laura Mar Fonseca1,2,3,4, Juliette Bignard1,2,3, Victor Galvan1,2,3, Andrea Peloso4, Thierry Berney2,5,6, Philippe Compagnon2,4, VANGUARD Consortium1,2,3, Ekaterine BERISHVILI1,2,3,4,5.

1Department of Surgery, Laboratory of Tissue Engineering and Organ Regeneration, University of Geneva, Geneva, Switzerland; 2Department of Surgery, Cell Isolation and Transplantation Center, University of Geneva, Geneva, Switzerland; 3Faculty Diabetes Center, University of Geneva, Geneva, Switzerland; 4Department of Surgery, Division of Transplantation, University of Geneva Hospitals, Geneva, Switzerland; 5Institute of Medical Research, Ilia State University, Tbilisi, Georgia; 6Service de transplantation, Néphrologie et Immunologie clinique, Hospices civils de Lyon, Lyon, France

VANGUARD Consortium.

Background: Our study aimed to generate a functional, prevascularized endocrine construct using amniotic membrane-derived hydrogel, islets, and blood outgrowth endothelial cells (BOECs) for transplantation into diabetic hosts.

Methods: Human amniotic membranes were decellularized, lyophilized, and solubilized to obtain hydrogels. To investigate the impact of these hydrogels on islet function in vitro, both rodent and human-derived islets and human BOECs were combined within the hydrogels and cultured in vasculogenic media to promote endothelial cell assembly into tubular, vascular-like structures. To assess in vivo function, vascularized constructs containing either 500 rat islet equivalents (IEQ) or 2000 human IEQ and 2× 10^5 BOECs were implanted subcutaneously in diabetic NSG mice. Control mice were transplanted with constructs containing islets only. Graft function was evaluated by measuring non-fasting blood glucose levels and performing intraperitoneal glucose tolerance tests (IPGTT). Graft morphology and vascularization were assessed using immunohistochemistry.

Results: Engineered vascularized constructs supported islet function and facilitated the development of an abundant, well-integrated vascular network with the islets. Blood glucose levels in mice transplanted with vascularized constructs normalized within 7 days, with long-term maintenance of normoglycemia. In contrast, most mice transplanted with islets combined in hydrogels remained diabetic. Histological analysis of explanted grafts revealed healthy islet morphology and successful revascularization. Experiments using human islets produced similar results, with rapid diabetes reversal and increased human C-peptide levels following transplantation. Explanted grafts exhibited excellent islet morphology, hormone expression, and, most importantly, intense vascularization. The presence of red blood cells within capillaries in the graft area and positive alpha SMA staining indicated functional and fully matured vessels inside the graft.

Conclusions: Our findings demonstrate that amnion-derived hydrogel seeded with endocrine pancreatic tissue and endothelial cells can be utilized for bioengineering functional, prevascularized endocrine constructs.

This work was supported by grants from the European Commission (Horizon 2020 Framework Program; VANGUARD grant 874700), the Juvenile Diabetes Research Foundation (JDRF; grant 3-SRA-2020-926-S-B), the Shota Rustaveli National Science Foundation (grant FR-19-19760) and the Swiss National Science Foundation (grant 310030_173138 and grant CRSII5_209417)..

Organized by

Supported by

Hosted by


IPITA-IXA-CTRMS Joint Congress • San Diego, CA, USA • October 26-29, 2023
© 2024 IPITA-IXA-CTRMS 2023